Yes, Spravato (esketamine) is a Schedule III controlled substance under federal law. That places it in the same regulatory category as drugs like testosterone and certain codeine combinations, meaning it has a recognized medical use but also a moderate potential for misuse or dependence. This classification shapes nearly everything about how the drug is prescribed, dispensed, and administered.
Why Spravato Is Classified as Schedule III
Spravato’s active ingredient, esketamine, is closely related to ketamine, a well-known anesthetic with established abuse potential. Esketamine is the more potent form of the ketamine molecule, and preclinical research shows it carries a greater risk for abuse-related behaviors than other forms of ketamine. In animal studies, esketamine produced reward-seeking behavior and other markers associated with misuse potential in humans.
The drug works by blocking a specific receptor in the brain that regulates glutamate, the brain’s main excitatory chemical messenger. This blockade triggers a cascade of effects: increased signaling between neurons, release of growth factors that help brain cells form new connections, and protein synthesis that strengthens neural pathways in the prefrontal cortex. These changes happen rapidly, which is why Spravato can improve depression symptoms within hours or days rather than the weeks typical of standard antidepressants. But the same fast-acting brain effects that make it therapeutically powerful also produce dissociation and sedation, contributing to its abuse potential and controlled substance status.
What the Controlled Status Means for Patients
Schedule III classification alone would impose prescribing and refill limits, but Spravato goes further. The FDA requires it to be distributed through a Risk Evaluation and Mitigation Strategy (REMS), a restricted program that adds layers of oversight beyond what most controlled substances require. In practical terms, this means you will never fill a Spravato prescription at a retail pharmacy or take it at home. The drug can only be dispensed to certified healthcare settings, and it must never be given directly to a patient for home use.
Before your first treatment, you’ll need to formally enroll in the REMS program by completing paperwork with your provider. You’ll receive counseling about the risks of sedation and dissociation. This enrollment must be verified before every single dose, not just the first one.
What a Treatment Session Looks Like
You self-administer the nasal spray under direct observation of a healthcare provider in a certified clinic or office. You don’t leave afterward. Federal requirements mandate at least two hours of monitoring following every dose. During that time, your blood pressure is checked before treatment, again at roughly 40 minutes (when the drug reaches peak levels in your body), and as needed until it returns to normal. Staff also monitor you for sedation and dissociation throughout the observation period.
After two hours, a provider assesses whether you’re clinically stable enough to leave. You cannot drive for the rest of the day after a session. The clinic then submits a monitoring form to the REMS program within seven days of each treatment, documenting what happened during your visit. This level of tracking applies to every session for as long as you receive the drug.
Who Spravato Is Approved For
The FDA has approved Spravato for two specific situations. The first is treatment-resistant depression in adults, meaning depression that hasn’t responded adequately to at least two different antidepressants. It can be used on its own or alongside an oral antidepressant for this indication. The second is depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior, where it’s used alongside an oral antidepressant.
One important clarification: Spravato has not been shown to prevent suicide or reduce suicidal thoughts or behavior. The FDA label states this explicitly. It also is not approved for use as an anesthetic, despite its chemical relationship to ketamine.
Cost and Insurance Coverage
The controlled substance restrictions and mandatory monitoring make Spravato more expensive than a typical prescription. The medication itself runs roughly $590 to $620 per dose at the 56 mg strength and $850 to $885 per dose at the 84 mg strength. On top of that, the facility monitoring fee typically adds $150 to $250 per session, bringing the total to somewhere between $750 and $1,100 per treatment.
Most major insurers, including Aetna, Cigna, Blue Cross Blue Shield, and UnitedHealthcare, cover Spravato for treatment-resistant depression, though coverage depends on your specific plan, deductible, and whether your provider is in-network. Prior authorization is standard, and insurers generally require documentation that previous antidepressants have failed before approving coverage.
Abuse Risk in Clinical Settings
The tightly controlled distribution system appears to be working as intended. Clinical studies of ketamine and esketamine administered in supervised medical settings have not shown patterns of misuse, dependence, diversion, or patients seeking the drug recreationally afterward. That said, most of those studies were retrospective and didn’t use standardized tools to formally measure abuse liability, so the evidence has limitations. The REMS program exists precisely because the theoretical risk is real, even if supervised use has been reassuring so far.